- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Triple class refractory/penta-refractory multiple myeloma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1000KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 337KB)
Selinexor – March 2022
Selinexor (TCR PR MM): Tablet 20 mg; Xpovio®
Last updated
30 May 2025